Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis in the Real-World

NCT05576779 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05576779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05576779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis in the Real-World
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
December 3, 2020
Completion date
December 31, 2021
Enrollment
2,101 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis